Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468382 | 0.92 | GAA (0.64) | GAATDP1TSHRGLAKMT2A | |
| SCHEMBL6504430 | 0.81 | KMT2A (0.74) | GAATSHRGLAKMT2AMEN1 | |
| SCHEMBL3339277 | 0.78 | TSHR (0.67) | GAATSHRGLAKMT2AHSD11B1 | |
| SCHEMBL14409571 | 0.78 | TSHR (0.70) | GAATSHRGLAKMT2AMEN1 | |
| SCHEMBL5790478 | 0.78 | KDM4E (0.68) | GAATDP1TSHRKMT2AMEN1 | |
| SCHEMBL2167020 | 0.77 | MAPT (0.64) | KMT2AMEN1KDM4EALDH1A1POLB | |
| SCHEMBL28363510 | 0.77 | POLB (0.76) | GAATDP1TSHRKMT2AKDM4E | |
| SCHEMBL3117118 | 0.77 | OPRM1 (0.50) | GAATDP1TSHRGLAKMT2A | |
| SCHEMBL4526644 | 0.77 | KDM4E (0.46) | GAATDP1TSHRGLAKMT2A | |
| SCHEMBL314589 | 0.76 | TSHR (0.75) | GAATSHRGLAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318447-A1 | N-[6-(4-MORPHOLINYL)-3-PYRIDINYL]-2-(TETRAHYDRO-2H-PYRAN-4-YL)-N-[(1--4-PIPERIDINYL) METHYL] ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYT1 TRANSPORT INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-1742940-A1 | N-[6-(4-MORPHOLINYL)-3-PYRIDINYL]-2-(TETRAHYDRO-2H-PYRAN-4-YL)-N-[(1-{[PHENYL]METHYL}-4-PIPERIDINYL)METHYL] ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYT1 TRANSPORT INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005103038-A1 | N-[6-(4-MORPHOLINYL)-3-PYRIDINYL]-2-(TETRAHYDRO-2H-PYRAN-4-YL)-N-[(1-{[PHENYL]METHYL}-4-PIPERIDINYL)METHYL] ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYT1 TRANSPORT INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005058882-A1 | COMPOUNDS HAVING MORPHOLINYL AND PIPERIDINYL GROUPS FOR USE AS GLYT1 AND GLYT2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318447-A1 | N-[6-(4-MORPHOLINYL)-3-PYRIDINYL]-2-(TETRAHYDRO-2H-PYRAN-4-YL)-N-[(1--4-PIPERIDINYL) METHYL] ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYT1 TRANSPORT INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA | SLC1A1, SLC1A2, SLC6A7 | GAA 1349/4885TDP1 2945/4885TSHR 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.